Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Stone Doggett

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
International Journal for Parasitology. Drugs and Drug Resistance|May 24, 2021
In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with Neospora caninum tachyzoites and Toxoplasma gondii oocystsDennis Imhof, Nicoleta Anghel, Pablo Winzer, et al.
Experimental Parasitology|January 10, 2017
Extended-spectrum antiprotozoal bumped kinase inhibitors: A reviewWesley C Van Voorhis, J Stone Doggett, Marilyn Parsons, et al.
The Journal of Infectious Diseases|November 14, 2018
Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against ToxoplasmosisMatthew A Hulverson, Igor Bruzual, Erin V McConnell, et al.
The Journal of Experimental Medicine|June 9, 2016
Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquoneLauren A Lawres, Aprajita Garg, Vidya Kumar, et al.
Journal of Medicinal Chemistry|April 12, 2014
Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethersAaron Nilsen, Galen P Miley, Isaac P Forquer, et al.
ACS Infectious Diseases|June 11, 2024
3-Position Biaryl Endochin-like Quinolones with Enhanced Antimalarial PerformanceSovitj Pou, Rolf W Winter, Rozalia A Dodean, et al.
Journal of Medicinal Chemistry|June 10, 2026
Revisiting 2-Substituted-4(1<i>H</i>)-Quinolones for Targeting the <i>Plasmodium falciparum</i> Cytochrome bc<sub>1</sub> ComplexSovitj Pou, Katherine M Liebman, Rolf W Winter, et al.
Journal of Medicinal Chemistry|June 17, 2016
Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of ToxoplasmosisRama Subba Rao Vidadala, Kasey L Rivas, Kayode K Ojo, et al.
ACS Medicinal Chemistry Letters|December 23, 2015
SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of <i>Toxoplasma gondii</i> CDPK1Wenlin Huang, Kayode K Ojo, Zhongsheng Zhang, et al.
Veterinary Parasitology|January 8, 2021
One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseasesWesley C Van Voorhis, Matthew A Hulverson, Ryan Choi, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
International Journal for Parasitology. Drugs and Drug Resistance|May 24, 2021
In vitro activity, safety and in vivo efficacy of the novel bumped kinase inhibitor BKI-1748 in non-pregnant and pregnant mice experimentally infected with Neospora caninum tachyzoites and Toxoplasma gondii oocystsDennis Imhof, Nicoleta Anghel, Pablo Winzer, et al.
Experimental Parasitology|January 10, 2017
Extended-spectrum antiprotozoal bumped kinase inhibitors: A reviewWesley C Van Voorhis, J Stone Doggett, Marilyn Parsons, et al.
The Journal of Infectious Diseases|November 14, 2018
Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against ToxoplasmosisMatthew A Hulverson, Igor Bruzual, Erin V McConnell, et al.
The Journal of Experimental Medicine|June 9, 2016
Radical cure of experimental babesiosis in immunodeficient mice using a combination of an endochin-like quinolone and atovaquoneLauren A Lawres, Aprajita Garg, Vidya Kumar, et al.
Journal of Medicinal Chemistry|April 12, 2014
Discovery, synthesis, and optimization of antimalarial 4(1H)-quinolone-3-diarylethersAaron Nilsen, Galen P Miley, Isaac P Forquer, et al.
ACS Infectious Diseases|June 11, 2024
3-Position Biaryl Endochin-like Quinolones with Enhanced Antimalarial PerformanceSovitj Pou, Rolf W Winter, Rozalia A Dodean, et al.
Journal of Medicinal Chemistry|June 10, 2026
Revisiting 2-Substituted-4(1<i>H</i>)-Quinolones for Targeting the <i>Plasmodium falciparum</i> Cytochrome bc<sub>1</sub> ComplexSovitj Pou, Katherine M Liebman, Rolf W Winter, et al.
Journal of Medicinal Chemistry|June 17, 2016
Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of ToxoplasmosisRama Subba Rao Vidadala, Kasey L Rivas, Kayode K Ojo, et al.
ACS Medicinal Chemistry Letters|December 23, 2015
SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of <i>Toxoplasma gondii</i> CDPK1Wenlin Huang, Kayode K Ojo, Zhongsheng Zhang, et al.
Veterinary Parasitology|January 8, 2021
One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseasesWesley C Van Voorhis, Matthew A Hulverson, Ryan Choi, et al.
Pageof 5